Loading
A phase 1/2 trial of PM8002, Ipilimumab, Cabozantinib in renal cell carcinoma, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) is a phase 1/2 interventional study registered as NCT07293351 by Bristol-Myers Squibb, with 474 participants planned, started 2026-03-26 and due to reach its primary completion in 2029-11-28. Interventions recorded: Pumitamig, Ipilimumab, Cabozantinib, Casdatifan. Conditions listed: Advanced Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, Ipilimumab, Bristol Myers Squibb.
Shares Ipilimumab, Bristol Myers Squibb, Renal cell carcinoma.
Shares PM8002, Bristol Myers Squibb.
Shares PM8002, Bristol Myers Squibb.
Shares Cabozantinib, Ipilimumab, Renal cell carcinoma.
Shares PM8002, Bristol Myers Squibb.
Shares PM8002, Bristol Myers Squibb.
Shares PM8002, Bristol Myers Squibb.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/